Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 6/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498743 | 1.00 | OXTR (0.41) | OXTRAVPR1AKDM4EHSD17B10MEN1 | |
| SCHEMBL28473802 | 0.91 | OXTR (0.50) | OXTRAVPR1AKDM4EMEN1KMT2A | |
| SCHEMBL28473805 | 0.91 | OXTR (0.50) | OXTRAVPR1AKDM4EMEN1KMT2A | |
| SCHEMBL28476929 | 0.91 | OXTR (0.50) | OXTRAVPR1AKDM4EMEN1KMT2A | |
| SCHEMBL15050220 | 0.85 | LMNA (0.44) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL1323564 | 0.85 | LMNA (0.44) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL13737372 | 0.85 | LMNA (0.44) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL1472102 | 0.81 | LMNA (0.44) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL22204407 | 0.75 | KDM4E (0.46) | KDM4EL3MBTL1OPRM1TSHR | |
| SCHEMBL3385520 | 0.75 | KCNH3 (0.42) | KDM4EHSD17B10MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | ELI LILLY AND COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4073051-B1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | LILLY CO ELI (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230013840-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YL-METHANAMINE | ELI LILLY AND COMPANY | 2023-01-19 | — | — | US | disclosed |
| US-20230013840-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YL-METHANAMINE | ELI LILLY AND COMPANY | 2023-01-19 | — | — | US | disclosed |
| EP-4073051-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | Eli Lilly and Company (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-114728923-A | Process and intermediates for the preparation of oxetan-2-ylmethylamines | 伊莱利利公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021118906-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | ELI LILLY AND COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021118906-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | ELI LILLY AND COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | CYP11B2, CYP11B1, MSMO1 | OXTR 4/4885AVPR1A 137/4885KDM4E 1293/4885 |
| US-20230013840-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YL-METHANAMINE | CYP11B2, CYP11B1, MSMO1 | OXTR 4/4885AVPR1A 137/4885KDM4E 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.